GSK’s Experimental Drug Shows Promise in Curing Chronic Hepatitis B

GSK has announced promising results from two key Phase 3 trials of bepirovirsen, an experimental drug for chronic hepatitis B. The treatment showed potential in achieving a functional cure, where the virus is suppressed enough for patients to discontinue therapy. Both studies, named B-Well 1 and B-Well 2, met their primary goals with encouraging outcomes for certain patient groups.

The trials involved over 1,800 participants across 29 countries. Patients received either bepirovirsen alongside standard nucleos(t)ide analogue therapy or the standard treatment alone. Those with lower baseline levels of hepatitis B surface antigen (HBsAg)—specifically below 1,000 IU/ml—experienced the most significant benefits.

Bepirovirsen combined with existing therapy resulted in a higher rate of functional cure compared to standard treatment alone. The drug also maintained a strong safety record, aligning with findings from earlier research. GSK plans to present the full findings at upcoming medical conferences. Chronic hepatitis B remains a global health challenge, affecting millions and often leading to severe liver complications. A functional cure, though not a complete eradication of the virus, could enable patients to manage the condition without lifelong medication.

The results could represent a significant advancement in hepatitis B treatment, particularly for patients with lower HBsAg levels. GSK’s data suggests bepirovirsen may offer a viable option for reducing viral load when used with existing therapies. Full details will be shared with the medical community in the coming months.